Earnings Feed
Start Free
Dyne Therapeutics, Inc.·4

Jun 30, 7:05 PM ET

Rhodes Jason P 4

Research Summary

AI-generated summary

Updated

Dyne Therapeutics (DYN) Director Jason P. Rhodes Sells Shares

What Happened

  • Jason P. Rhodes, a director of Dyne Therapeutics (DYN), disposed of a total of 504,695 shares in open-market sales on June 26 and June 29, 2026, generating aggregate proceeds of approximately $10.7 million. The June 26 blocks reported a weighted-average price of $21.28; the June 29 blocks reported a weighted-average price of $21.14. These transactions are sales (code S) and represent liquidity rather than a purchase-based bullish signal.

Key Details

  • Transaction dates and amounts:
    • 2026-06-26: 162,954 shares @ $21.28 = $3,467,661 (F2)
    • 2026-06-26: 81,903 shares @ $21.28 = $1,742,896 (F2)
    • 2026-06-26: 64,411 shares @ $21.28 = $1,370,666 (F2)
    • 2026-06-29: 102,969 shares @ $21.14 = $2,176,765 (F6)
    • 2026-06-29: 51,756 shares @ $21.14 = $1,094,122 (F6)
    • 2026-06-29: 40,702 shares @ $21.14 = $860,440 (F6)
    • Total: 504,695 shares; total proceeds ≈ $10,712,550.
  • Filing: Form 4 filed June 30, 2026, reporting transactions on June 26 and June 29, 2026 (appears filed within the typical 2-business-day window).
  • Plan and price details: Sales were made pursuant to a Rule 10b5-1 trading plan adopted March 19, 2026 (F1). Reported prices are weighted averages; individual sale prices ranged (per footnotes) from $21.00 up to $21.61 and up to $21.3247 for the separate groups (F2, F6).
  • Ownership/beneficial interest: Several blocks were held by Atlas Venture partnership entities (Atlas Venture Fund XI, Atlas Venture Opportunity Fund I & II, AVA partnerships). Rhodes disclaims Section 16 beneficial ownership of those fund-held securities except to the extent of any pecuniary interest (F3–F5, F7).
  • Shares owned after transaction: Not specified in the provided filing excerpt.

Context

  • These were planned, pre-arranged sales (10b5-1), a common mechanism for insiders to sell shares without running afoul of insider-trading rules. Because the shares were held via venture funds and the reporting person disclaims beneficial ownership for many blocks, these transactions reflect institutional/fund dispositions more than a personal purchase decision. Sales do not by themselves indicate company fundamentals; retail investors often weigh insider purchases more heavily as signals.